Drew CroninFine - Relief Therapeutics Exec Marketing
| RLFTF Stock | USD 5.36 0.22 3.94% |
Insider
Drew CroninFine is Exec Marketing of Relief Therapeutics Holding
| Phone | 41 44 723 59 59 |
| Web | https://www.relieftherapeutics.com |
Relief Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3257) %, meaning that it generated substantial loss on money invested by shareholders. Relief Therapeutics' management efficiency ratios could be used to measure how well Relief Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | INSIDER Age | ||
| Adi YarelToledano | Valens | 46 | |
| Massad Eyal | Valens | 66 | |
| Moshe Lichtman | Valens | 62 | |
| Peter Mertens | Valens | N/A | |
| Gregory Henderson | Analog Devices | 55 | |
| Gabi Shriki | Valens | 56 | |
| Michael Linse | Valens | 45 | |
| Gaby Cohen | Valens | 57 | |
| Yahal Zilka | Valens | 63 | |
| Eyal Kishon | Valens | 60 | |
| Gideon Keden | Valens | 59 | |
| Nadav Banet | Valens | 57 | |
| Ker Zhang | Valens | 56 | |
| Alon Benzaray | Valens | 54 | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 |
Relief Therapeutics Leadership Team
Elected by the shareholders, the Relief Therapeutics' board of directors comprises two types of representatives: Relief Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relief. The board's role is to monitor Relief Therapeutics' management team and ensure that shareholders' interests are well served. Relief Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relief Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeremy CPA, CFO Officer | ||
| David McCullough, Sr Access | ||
| DPhil MBA, Chief Officer | ||
| Jeremy Meinen, Chief Admin | ||
| Dorian Bevec, Chief Lifescience | ||
| Drew CroninFine, Exec Marketing | ||
| Christopher Wick, Sr Sales | ||
| Paolo Galfetti, COO Director | ||
| Marco Marotta, Chief Officer | ||
| Jack Weinstein, Treasurer CFO | ||
| Anthony Kim, Sr Operations | ||
| Jack MBA, Chief Officer | ||
| Serene MPH, VP Medicine |
Relief Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Relief Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 102.36 M | |||
| Shares Outstanding | 4.39 B | |||
| Shares Owned By Insiders | 3.68 % | |||
| Shares Owned By Institutions | 22.16 % | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 22.16 X | |||
| Revenue | 3.32 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Relief OTC Stock
Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.